Immune check-point in endometrial cancer

被引：28

作者：

De Felice, Francesca ^{[1
]}

Marchetti, Claudia ^{[2
]}

Tombolini, Vincenzo ^{[1
]}

Panici, P. Benedetti ^{[3
]}

机构：

[1] Sapienza Univ Rome, Policlin Umberto 1, Dept Radiotherapy, Viale Regina Elena 326, I-00161 Rome, Italy

[2] Fdn Policlin Univ A Gemelli IRCCS, Div Gynecol Oncol, Rome, Italy

[3] Sapienza Univ Rome, Dept Gynecol Obstet Sci & Urol Sci, Rome, Italy

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 24卷 / 08期

关键词：

Endometrial cancer; Immunotherapy; Immune check-point; Survival; Microsatellite instability; Mismatch repair; MISMATCH REPAIR STATUS; WOMEN; BLOCKADE; TUMORS; PEMBROLIZUMAB; ASSOCIATION; CARCINOMAS; EXPRESSION; OUTCOMES; PD-1;

D O I：

10.1007/s10147-019-01437-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Endometrial cancer (EC) is one of the most frequent tumors in women. Despite recent advances in treatment approaches, the prognosis in advanced, recurrent, or metastatic disease remains poor. The aim was to provide the clinician with an update, the current status, and the new developments in the management of EC. Based on the new EC molecular classification, we focused on the impact of immune check-point inhibitors. Methods Pivotal trials, published literature, and conference proceedings were reviewed. PubMed and Scopus databases were searched to select English-language articles. Results Immune check-point inhibitors are the subject of ongoing studies and their benefit seems to be related to microsatellite instability (MSI) status. Conclusions Immune check-point inhibitors should be considered a promising treatment option to better personalize therapeutic strategies in EC.

引用

页码：910 / 916

页数：7

共 50 条

[1] Immune check-point in endometrial cancer
Francesca De Felice
Claudia Marchetti
Vincenzo Tombolini
P. Benedetti Panici
[J]. International Journal of Clinical Oncology, 2019, 24 : 910 - 916
[2] Immune check-point in cervical cancer
De Felice, F.
Marchetti, C.
Palaia, I.
Ostuni, R.
Muzii, L.
Tombolini, V.
Panici, P. Benedetti
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 129 : 40 - 43
[3] The Glycocode of the tumormicroenvironment in cancer, a novel immune check-point
Rodriquez, E.
Schetters, S.
van Vliet, S.
Boelaars, K.
Giovanetti, E.
Garcia-Vallejo, J.
van Kooyk, Y.
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 234 - 235
[4] Immune check-point in glioblastoma multiforme
De Felice, F.
Pranno, N.
Marampon, F.
Musio, D.
Salducci, M.
Polimeni, A.
Tombolini, V.
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 138 : 60 - 69
[5] The Glycocode of the tumormicroenvironment in pancreatic cancer, a novel immune check-point
Rodriquez, E.
Giovanetti, E.
van Vliet, S.
Garcia-Vallejo, J.
van Kooyk, Y.
[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1560 - 1560
[6] Orchestrating immune check-point blockade for cancer immunotherapy in combinations
Luis Perez-Gracia, Jose
Labiano, Sara
Rodriguez-Ruiz, Maria E.
Sanmamed, Miguel F.
Melero, Ignacio
[J]. CURRENT OPINION IN IMMUNOLOGY, 2014, 27 : 89 - 97
[7] Glycocode of the tumormicroenvironment a novel immune check-point
Van Kooyk, Yvette
[J]. GLYCOBIOLOGY, 2021, 31 (12) : 1729 - 1730
[8] Cholangiocarcinoma: Era of Immune Check-Point Inhibitors
El Hag, Mohamed I.
Wood-Trageser, Michelle
Patel, Krishna
Specht, Susan
Sasatomi, Eizaburo
Sun, Weijing
Demetris, Anthony
[J]. MODERN PATHOLOGY, 2018, 31 : 633 - 633
[9] The Check-Point
Foster, Nick
[J]. STAND, 2018, 16 (02): : 88 - 88
[10] Cholangiocarcinoma: Era of Immune Check-Point Inhibitors
El Hag, Mohamed I.
Wood-Trageser, Michelle
Patel, Krishna
Specht, Susan
Sasatomi, Eizaburo
Sun, Weijing
Demetris, Anthony
[J]. LABORATORY INVESTIGATION, 2018, 98 : 633 - 633

← 1 2 3 4 5 →